Sitemap
Pages
Posts
- Gedeon Richter and Myovant Sciences Receive Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Uterine Fibroids
- Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
- Richter announces the acquisition of Finox Holding
- Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
- Full Results of PEARL IV Study presented at the European Society of Gynaecological Endoscopy (ESGE) congress confirms the efficacy of ulipristal acetate 5 mg for the long term management of uterine fibroids
- European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)
- Efficacy and Safety of repeated use of ulipristal acetate in uterine fibroids
- Long-term treatment of uterine fibroids with ulipristal acetate
- European Commission approves Esmya® Type II variation, allowing a repeated course of 3-month treatment for uterine fibroids
- European Commission approves Esmya® for the pre-operative treatment of uterine fibroids (myomas)
- Ulipristal acetate versus leuprolide acetate for uterine fibroids
- PEARL I and II studies published in New England Journal of Medicine confirm the efficacy of Esmya® (ulipristal acetate) for the pre-operative treatment of uterine fibroids (myomas)
- Richter announces that PregLem, its wholly owned subsidiary, receives positive EMA/CHMP opinion for Esmya® for the pre-operative treatment of uterine fibroids (myomas)
- Richter and Watson Announce Exclusive License Agreement for Esmya™
- EBCOG 2010 (Antwerp)
- Richter Announces the Acquisition of PregLem
- PregLem announces in-licensing deal with Merck Serono for post-operative adhesions & endometriosis
- PregLem announces positive phase III results for ESMYA™
- PregLem announces positive phase III results for ESMYA as an effective treatment for uterine fibroids
- PregLem licenses additional rights for ulipristal acetate from HRA Pharma to develop a first-in-class myoma (fibroids) treatment for North American market
Careers
A career at Preglem® is more than just a job. It gives you the opportunity to solve challenging global problems in a way that can change the world.
Contact us
In line with our corporate culture, we treat all information received with full confidentiality.